Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 1, 2014, Pages 62-72

  Lluch, Ana ^a   Álvarez, Isabel ^b   Muñoz, Montserrat ^c   Seguí, Miguel Ángel ^d   Tusquets, Ignasi ^e   García Estévez, Laura ^f  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d Servicio de Cirugía General Y Aparato Digestivo   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f Centro Integral Oncologico Clara Campal   (Spain)

Author keywords

Chemotherapy; Metastatic breast cancer; Nab paclitaxel; SPARC; Taxane

Indexed keywords

ALBUMIN; DOCETAXEL; OSTEONECTIN; PACLITAXEL;

ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTHRALGIA; ASTHENIA; BREAST METASTASIS; CANCER INHIBITION; CANCER RECURRENCE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; ENDOTHELIUM CELL; FATIGUE; HUMAN; INFECTION; MUCOSA INFLAMMATION; MYALGIA; NANOPHARMACEUTICS; NANOTECHNOLOGY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

CHEMOTHERAPY; METASTATIC BREAST CANCER; NAB-PACLITAXEL; SPARC; TAXANE;

ALBUMINS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASM METASTASIS; PACLITAXEL; RESEARCH; TAXOIDS; TREATMENT OUTCOME;

EID: 84890878059     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.08.001     Document Type: Review

References (39)

1. Sledge G.W., Neuberg D., Bernardo P., Ingle J.N., Martino S., Rowinsky E.K., et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003, 21:588-592.
2. Cavallo J. Can you afford cancerα 2006, Available at: http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/365 (accessed 13.07.12).
3. Brouwer E., Verweij J., De Bruijn P., Loos W.J., Pillay M., Buijs D., et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos 2000, 28:1141-1145.
4. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37:1590-1598.
5. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990, 8:1263-1268.
6. Trieu V., Frankel T., Labao E., Soon-Shiong P., Desai N.P. SPARC expression in breas tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol. Proc Am Assoc Cancer Res 2005, 46:5584.
7. McNeil S.E. Nanoparticle therapeutics: a personal perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1:264-271.
8. Cuenca A.G., Jiang H., Hochwald S.N., Delano M., Cance W.G., Grobmyer S.R. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 2006, 107:459-466.
9. Gelfand V.I., Bershadsky A.D. Microtubule dynamics: mechanism, regulation, and function. Annu Rev Cell Biol 1991, 7:93-116.
10. Rowinsky E.K., Calvo E. Novel agents that target tublin and related elements. Semin Oncol 2006, 33:421-435.
11. Brekken R.A., Sage E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 2001, 19:816-827.
12. Gardner E.R., Dahut W.L., Scripture C.D., Jones J., Aragon-Ching J.B., Desai N., et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008, 14:4200-4205.
13. Aapro M.S., Von Minckwitz G. Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancer. EJC Suppl 2008, 6:3-11.
14. ten Tije A.J., Verweij J., Loos W.J., Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003, 42:665-685.
15. van Tellingen O., Huizing M.T., Panday V.R., Schellens J.H., Nooijen W.J., Beijnen J.H. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999, 81:330-335.
16. Winer E.P., Berry D.A., Woolf S., Duggan D., Kornblith A., Harris L.N., et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004, 22:2061-2068.
17. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002, 8:1038-1044.
18. Nyman D.W., Campbell K.J., Hersh E., Long K., Richardson K., Trieu V., et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005, 23:7785-7793.
19. Kearns C.M. Pharmacokinetics of the taxanes. Pharmacotherapy 1997, 17:105S-109S.
20. Mross K., Hollander N., Hauns B., Schumacher M., Maier-Lenz H. The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol 2000, 45:463-470.
21. Podhajcer O.L., Benedetti L., Girotti M.R., Prada F., Salvatierra E., Llera A.S. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008, 27:523-537.
22. Chin D., Boyle G.M., Williams R.M., Ferguson K., Pandeya N., Pedley J., et al. Novel markers for poor prognosis in head and neck cancer. Int J Cancer 2005, 113:789-797.
23. Koukourakis M.I., Giatromanolaki A., Brekken R.A., Sivridis E., Gatter K.C., Harris A.L., et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003, 63:5376-5380.
24. Watkins G., Douglas-Jones A., Bryce R., Mansel R.E., Jiang W.G. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 2005, 72:267-272.
25. Yardley D.A., Daniel B.R., Inhorn R.C., Vazquez E.R., Trieu V.N., Motamed K., et al. SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC). ASCO Meeting Abstract 2010, 28:10574.
26. Nagai M.A., Gerhard R., Fregnani J.H., Nonogaki S., Rierger R.B., Netto M.M., et al. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 2011, 126:1-14.
27. Blackwell K.L., Hamilton E.P., Rocha G., Gainey M., Trieu V., Motamed P., et al. SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel (nab-P)/carboplatin (C)/bevacizumab (B) for triple negative metastatic breast cancer (TNMBC). 35th ESMO Congress 2010, Abstract 4976.
28. Desai N.P., Trieu V., Hwang L.Y., Wu R., Soon-Shiong P., Gradishar W.J. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008, 19:899-909.
29. O'Shaughnessy J., Gradishar W.J., Bhar P., Iglesias J. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat 2013, 138:829-837.
30. Ibrahim N.K., Samuels B., Page R., Doval D., Patel K.M., Rao S.C., et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005, 23:6019-6026.
31. Blum J.L., Savin M.A., Edelman G., Pippen J.E., Robert N.J., Geister B.V., et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007, 7:850-856.
32. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
33. Gradishar W.J., Krasnojon D., Cheporov S., Makhson A.N., Manikhas G.M., Clawson A., et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009, 27:3611-3619.
34. Gradishar W.J., Krasnojon D., Cheporov S.V., Makhson A., Manikhas G.M., Clawson A., et al. Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial. ASCO Meeting Abstract 2011, 29:275.
35. Abraxane® (nab-paclitaxel) Summary of product characteristics 2013, Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000778/WC500020435.pdf (accessed 13.07.12).
36. Abraxane® (nab-paclitaxel) Summary of product characteristics 2013, Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021660s025s026s029lbl.pdf (accessed 13.07.12).
37. Rugo H.S., Barry W.T., Moreno-Aspitia A., Lyss A.P., Cirrincione C., Mayer EL, et al. CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). ASCO Meeting Abstracts 2013, 30:CRA1002.
38. Lazzaro C., Bordonaro R., Cognetti F., Fabi A., De Placido S., Arpino G., et al. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. Clinicoecon Outcomes Res 2013, 5:125-135.
39. Yamamoto Y., Kawano I., Iwase H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther 2011, 4:123-136.